Pfizer Announces Acquisition of Metsera, Inc.

Summary

On September 21, 2025, Pfizer Inc. announced the acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company specializing in obesity and cardiometabolic disease treatments. The transaction is valued at $4.9 billion, with an additional contingent value right of up to $22.50 per share tied to clinical and regulatory milestones. The acquisition is expected to close in the fourth quarter of 2025, subject to regulatory approvals and shareholder approval. Executive officers of Metsera have also entered into agreements to offset excise tax liabilities on certain payments.